Navigation Links
Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel,Anticancer Agents, at AACR

of effect. We anticipate selecting a lead candidate from our family of NEIs to advance into investigational new drug (IND) enabling studies in the near term."

Data on Kosan's NEIs were presented in two posters at the 2007 Annual Meeting of the American Association for Cancer Research (AACR), being held in Los Angeles, CA.

    -- Abstract 5609:  "Nuclear Export Inhibitors (NEIs) as Novel Cancer

       Therapeutics" presents results from analyses of the in vitro activity

       of NEIs showing that upon the addition of low nanomolar concentrations

       of polyketide-based nuclear export inhibitors to cancer cells, the

       accumulation of CRM1-dependent cargo proteins sequestered in the

       nucleus is detected rapidly. Results also show that exposure to NEIs

       causes an increase in multiple markers of apoptosis including plasma

       membrane alterations (Annexin V binding) and caspase activation in

       cancer cells. NEI treatment induces cell cycle arrest, but not

       apoptosis, in normal cells. NEIs show potent activity as single agents

       in in vivo tumor models and may also have application in combination

       therapies as NEIs are synergistic when combined with a broad spectrum

       of cancer therapeutics in in vitro experiments.

    -- Abstract 5597:  "Anti-Tumor Activity of Novel Nuclear Export Inhibitors

       (NEIs) in Multiple Xenograft Models" presents data on two members of

       Kosan's lead NEI series which are shown to have a wide therapeutic

       window in several in vivo xenograft models, including human tumor

       xenograft models of cervical cancer, colon cancer, breast cancer,

       non-small cell lung cancer, melanoma and leukemia. Kosan's lead NEI

       analogs have a high level of tolerability and demonstrated efficacy,

       and represent potentially novel anticancer agents.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classe
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:12/24/2014)... 24, 2014  Conkwest, Inc., the Natural Killer ... Natural Killer (NK) cell-line platform, Neukoplast® (NK-92™) as ... Soon-Shiong , NantWorks founder, physician scientist and biotechnology ... purchase approximately $48 million of the Company,s Class ... he will be named Co-Chairman of the Conkwest ...
(Date:12/24/2014)... and LONDON , December 24, 2014 ... are expected to grow at an average rate of ... value and volume. Hip, knee and spine surgeries are ... in emerging economies they have a lower penetration. Increased ... the use of composites. Non-metallic orthopedic devices have gained ...
(Date:12/24/2014)... Wash. , Dec. 23, 2014  Advanced ... development company engaged primarily in the development of ... therapeutic applications, today announced that it has filed ... Food and Drug Administration ("FDA") for marketing clearance ... Section 513(f)(2) of the U.S. Food, Drug and ...
Breaking Medicine Technology:Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... in bone mineral density at the,lumbar spine and ... salmeterol inhalation powder) and salmeterol, - Study ... in patients,with COPD, PHILADELPHIA, Oct. 29 ... three-year study of patients with,Chronic Obstructive Pulmonary Disease ...
... Cryoablation ... Treatment Technology, PLEASANTON, ... (ACOSOG) which just initiated a National Cancer,Institute (NCI) funded clinical ... Therapy in the Treatment of Invasive Breast,Carcinoma," has selected the ...
Cached Medicine Technology:Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD 2Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD 3NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation 2NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation 3
(Date:12/24/2014)... For chic ladies, new fashionable outfits are necessary ... their Holiday Wish List, Angeldress.co.uk has chosen some ... accent ladies’ holiday wardrobe by launching a promotion on its ... the discount of 80% off, like a cheap suit. , ... company’s chic wedding dresses are among the hottest items in ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 The report ... regards to the various market dynamics such as the ... assisted arthroscopy, the wait time for U.S. sports medicine, ... medicine market, and the challenges faced by the market. ... http://www.researchmoz.us/global-sports-medicine-market-report-2014-edition-report.html , The report also provides an overview ...
(Date:12/24/2014)... Plantation, FL (PRWEB) December 24, 2014 ... permanent solution for a tooth replacement. They offer the ... boast several advantages over other forms of tooth replacement. ... not rely on the adjacent teeth for support, and ... many people have been told that they are not ...
(Date:12/24/2014)... Viejo, California (PRWEB) December 24, 2014 ... release of the ProDenoise from Pixel Film Studios. , “The ... noise or grain in their footage,” said Christina Austin, CEO ... have in any Final Cut Pro X editors toolbox.” , ... film noise or grain in their footage with ProDenoise from ...
(Date:12/24/2014)... Dennis Thompson HealthDay Reporter ... good news about the experimental Ebola vaccine that U.S. officials ... shows a precursor of that vaccine produced a safe ... of the vaccine, when given to more than 100 Ugandans ... white blood cells that could potentially protect a person against ...
Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Starts Its Big Sales by Offering Various Kinds of Cheap Clothes and Fashion Accessories 2Health News:Sports Medicine Market Report 2014: Global Industry Analysis, Share, Size, Trends, Growth and Forecast report 2Health News:Innovative Dental Implant Procedure to Gain Momentum in the New Year 2Health News:Pixel Film Studios released the ProDenoise plugin for Final Cut Pro X today. 2Health News:Early Study Offers Hope for an Ebola Vaccine 2Health News:Early Study Offers Hope for an Ebola Vaccine 3Health News:Early Study Offers Hope for an Ebola Vaccine 4
... Amanda Gardner HealthDay Reporter , TUESDAY, April ... the middle ground with its new drug control policy, ... Tuesday, rejects both the harsh "war on drugs" ... the push to legalize illegal drugs. Gil Kerlikowske, ...
... HOUSTON - Scientists who developed a technology for identifying and ... have found a way to penetrate the outer membrane and ... the cell. In a paper published today online in ... The University of Texas MD Anderson Cancer Center reports packaging ...
... , TUESDAY, April 17 (HealthDay News) -- The ... apparently because of changes in the brain,s white matter, a ... aged 21 to 85, to perform a learning task involving ... that age-related declines in decision-making are associated with the weakening ...
... , TUESDAY, April 17 (HealthDay News) -- ... reduce the spread of the AIDS-causing virus, but would ... high risk for HIV infection, according to a new ... to analyze the use of the combination drug tenofovir-emtricitabine ...
... By Maureen Salamon HealthDay Reporter , TUESDAY, April ... patients, own tumor cells led to a nearly 50 percent ... the same malignancy that claimed the life of U.S. Sen. ... multicenter trial of about 40 patients with recurrent glioblastoma -- ...
... bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell ... in 2006 did not lead to significantly increase survival ... Medicare, a new study by Dana-Farber Cancer Institute researchers has ... 18 Journal of the American Medical Association , a ...
Cached Medicine News:Health News:White House Drug Policy Shifts Strategy 2Health News:White House Drug Policy Shifts Strategy 3Health News:Scientists tailor cell surface targeting system to hit organelle ZIP codes 2Health News:Scientists tailor cell surface targeting system to hit organelle ZIP codes 3Health News:HIV Prevention Pill Cost-Effective for High-Risk Men: Study 2Health News:Brain Tumor Vaccine Shows Promise in Early Trial 2Health News:Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients 2
... The SkanWasher 400 is ... microplate washer with built-in ... The individual pressure settings ... very gentle wash to ...
Lab-Reader...
Fully automatic NRTL and CE certified microplate reader....
... a compact and versatile multilabel ... design allows up to six ... counting, luminescence, absorbance, and fluorescence ... and fluorescence polarization all on ...
Medicine Products: